Association of polymorphism in FcGR3A gene and progression of low-grade precursor lesions of cervical carcinoma

Human Immunology

Volumn 71, Issue 3, 2010, Pages 314-317

  Conesa Zamora, P ^a   Santaclara, V ^a   Gadea Ninoles E ^a   Ortiz Reina, S ^a   Perez Guillermo, M ^a  

^a Hospital Universitario SM Rosell HUSMR   (Spain)

Author keywords

Cervical carcinogenesis; FcGR3A; Genetic susceptibility; Human papillomavirus; Squamous intraepithelial lesion

Indexed keywords

IMMUNOGLOBULIN RECEPTOR; PROTEIN FCGR3A; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER GRADING; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS INFECTION; VIRUS STRAIN; WART VIRUS;

ADULT; CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; COMORBIDITY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMORPHISM, GENETIC; RECEPTORS, IGG; RETROSPECTIVE STUDIES; RISK FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 76949106065     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2009.11.012     Document Type: Article

References (34)

1. zur Hausen H. Papillomaviruses and cancer: From basic studies to clinical application. Nat Rev Cancer 2 (2002) 342-350
2. Muñoz N., Bosch F.X., de Sanjosé S., Herrero R., Castellsagué X., Shah K.V., et al., International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 (2003) 518-527
3. Tindle R.W. Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer 2 (2002) 59-65
4. Wang S.S., and Hildesheim A. Chapter 5: Viral and host factors in human papillomavirus persistence and progression. J Natl Cancer Inst Monogr 31 (2003) 35-40
5. Zehbe I., Mytilineos J., Wikström I., Henriksen R., Edler L., and Tommasino M. Association between human papillomavirus 16 E6 variants and human leukocyte antigen class I polymorphism in cervical cancer of Swedish women. Hum Immunol 64 (2003) 538-542
6. Wang S.S., Wheeler C.M., Hildesheim A., Schiffman M., Herrero R., Bratti M.C., et al. Human leukocyte antigen class I and II alleles and risk of cervical neoplasia: Results from a population-based study in Costa Rica. J Infect Dis 184 (2001) 1310-1314
7. Karassa F.B., Trikalinos T.A., and Ioannidis J.P. The role of FcgammaRIIA and IIIA polymorphisms in autoimmune diseases. Biomed Pharmacother 58 (2004) 286-291
8. van der Pol W., and van de Winkel J.G. IgG receptor polymorphisms: Risk factors for disease. Immunogenetics 48 (1998) 222-232
9. Emonts M., Hazelzet J.A., de Groot R., and Hermans P.W. Host genetic determinants of Neisseria meningitidis infections. Lancet Infect Dis 3 (2003) 565-577
10. Rekand T., Langeland N., Aarli J.A., and Vedeler C.A. Fcgamma receptor IIIA polymorphism as a risk factor for acute poliomyelitis. J Infect Dis 186 (2002) 1840-1843
11. Da Silva D.M., Fausch S.C., Verbeek J.S., and Kast W.M. Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcgamma receptors and contributes to acquisition of T cell immunity. J Immunol 178 (2007) 7587-7597
12. Conesa-Zamora P., Ortiz-Reina S., Moya-Biosca J., Doménech-Peris A., Orantes-Casado F.J., Pérez-Guillermo M., et al. Genotype distribution of human papillomavirus (HPV) and coinfections in cervical cytologic specimens from two outpatient gynecological clinics in a region of southeast Spain. BMC Infect Dis 9 (2009) 124
13. Solomon D., Davey D., Kurman R., Moriarty A., O'Connor D., Prey M., et al., Forum Group Members, Bethesda 2001 Workshop. The 2001 Bethesda system: Terminology for reporting results of cervical cytology. JAMA 287 (2002) 2114-2119
14. Gomez-Roman J.J., Echevarria C., Salas S., González-Morán M.A., Perez-Mies B., García-Higuera I., et al. A type-specific study of human papillomavirus prevalence in cervicovaginal samples in three different Spanish regions. APMIS 117 (2009) 22-27
15. Kim D.H., Jung H.D., Kim J.G., Lee J.J., Yang D.H., Park Y.H., et al. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 108 (2006) 2720-2725
16. Lai H.C., Sytwu H.K., Sun C.A., Yu M.H., Yu C.P., Liu H.S., et al. Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis. Int J Cancer 103 (2003) 221-225
17. Ueda M., Hung Y.C., Terai Y., Yamaguchi H., Saito J., Nunobiki O., et al. Fas gene promoter -670 polymorphism (A/G) is associated with cervical carcinogenesis. Gynecol Oncol 98 (2005) 129-133
18. Conesa-Zamora P., Doménech-Peris A., Orantes-Casado F.J., Sahuquillo-Frias L., Ortiz-Reina S., Acosta-Ortega J., et al. Effect of human papillomavirus on cell cycle related proteins p16, Ki67, cyclin D1, p53 and ProEx C in precursor lesions of cervical carcinoma. A tissue microarray study. Am J Clin Pathol 132 (2009) 378-390
19. Conesa-Zamora P., Doménech-Peris A., Ortiz-Reina S., Orantes-Casado F.J., Acosta-Ortega J., García-Solano J., et al. Immunohistochemical evaluation of ProEx C in human papillomavirus-induced lesions of the cervix. J Clin Pathol 62 (2009) 159-162
20. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci 110 (2006) 525-541
21. + CTL responses in vivo. J Immunol 168 (2002) 2240-2246
22. Rafiq K., Bergtold A., and Clynes R. Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest 110 (2002) 71-79
23. Caberg J.H., Hubert P., Herman L., Herfs M., Roncarati P., Boniver J., et al. Increased migration of Langerhans' cells in response to HPV16 E6 and E7 oncogene silencing: Role of CCL20. Cancer Immunol Immunother 58 (2009) 39-47
24. Jimenez-Flores R., Mendez-Cruz R., Ojeda-Ortiz J., Muñoz-Molina R., Balderas-Carrillo O., de la Luz Diaz-Soberanes M., et al. High-risk human papilloma virus infection decreases the frequency of dendritic Langerhans' cells in the human female genital tract. Immunology 117 (2006) 220-228
25. Guess J.C., and McCance D.J. Decreased migration of langerhans precursor-like cells in response to human keratinocytes expressing human papillomavirus type 16 E6/E7 is related to reduced macrophage inflammatory protein-3alpha production. J Virol 79 (2005) 14852-14862
26. Ho G.Y., Bierman R., Beardsley L., Chang C.J., and Burk R.D. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338 (1998) 423-428
27. Castellsagué X., de Sanjosé S., Aguado T., Laurie K.S., Bruni L., Muñoz J., et al., WHO/ICO Information Centre on HPV and Cervical Cancer. HPV and cervical cancer in the 2007 report. Vaccine 25 (2007) C1-C230
28. Peto J., Gilham C., Fletcher O., and Matthews F.E. The cervical cancer epidemic that screening has prevented in the UK. Lancet 364 (2004) 249-256
29. Wu J., Edberg J.C., Redecha P.B., Bansal V., Guyre P.M., Coleman K., et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 100 (1997) 1059-1070
30. Wilting S.M., Steenbergen R.D., Tijssen M., van Wieringen W.N., Helmerhorst T.J., van Kemenade F.J., et al. Chromosomal signatures of a subset of high-grade premalignant cervical lesions closely resemble invasive carcinomas. Cancer Res 69 (2009) 647-655
31. van Dongen J.J., Langerak A.W., Brüggemann M., Evans P.A., Hummel M., Lavender F.L., et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17 (2003) 2257-2317
32. Georgopoulos N.T., Proffitt J.L., and Blair G.E. Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain, TAP1 and LMP2 genes by the human papillomavirus (HPV) type 6b, 16 and 18 E7 oncoproteins. Oncogene 19 (2000) 4930-4935
33. Nees M., Geoghegan J.M., Hyman T., Frank S., Miller L., and Woodworth C.D. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J Virol 75 (2001) 4283-4296
34. Ueda M., Toji E., Nunobiki O., Izuma S., Okamoto Y., Torii K., et al. Germline polymorphism of cancer susceptibility genes in gynecological cancer. Hum Cell 21 (2008) 95-104